Q-omics provides the consensus-scored DMRTB1 profile across patient tissues and cancer cell-line models. DMRTB1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, DMRTB1 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, DMRTB1 RNA expression shows 5,999 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight OV, THCA, and KIRC as cancer lineages where DMRTB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DMRTB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DMRTB1 survival associations across molecular data types. DMRTB1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DMRTB1 RNA expression–survival associations across cancer types. High DMRTB1 expression shows unfavorable associations in KICH, MESO, UCEC and LUSC, but favorable associations in OV and LGG. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify OV as the clearest survival context for DMRTB1 RNA expression.
This table summarizes DMRTB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DMRTB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DMRTB1 shows lower tumor expression in THCA and higher tumor expression in UCEC, LUAD and LIHC. The THCA box plot shows higher DMRTB1 RNA expression in normal versus tumor tissue (log2 FC = −0.549, t-test p = .019).
This table shows molecular features associated with DMRTB1 in patient tissues and cancer cell lines. In patient samples, DMRTB1 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, DMRTB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
